The GLP-1 class was designed to lower blood sugar and, eventually, body weight. The cardiovascular outcome trials were required by the FDA as safety checks — not expected to show benefit. They showed benefit. That reversal in understanding is still working its way through how clinicians and patients think about these drugs.
The Trials That Changed the Framing
After a previous diabetes drug (rosiglitazone) raised cardiovascular concerns, the FDA mandated that all new diabetes medications demonstrate cardiovascular safety in large outcome trials. Novo Nordisk ran LEADER for liraglutide and SUSTAIN-6 for semaglutide with that goal: prove the drugs don't cause heart attacks.
Both trials found the opposite. LEADER (2016) showed a 13% reduction in major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — compared to placebo, with cardiovascular death itself reduced by a statistically significant margin. SUSTAIN-6 showed a 26% reduction in MACE for semaglutide, driven primarily by stroke reduction. These weren't small effects in small populations. LEADER enrolled over 9,000 patients with type 2 diabetes and established cardiovascular disease; SUSTAIN-6 enrolled over 3,200.
Definition(What MACE means)
MACE stands for Major Adverse Cardiovascular Events — the composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death. It's the primary endpoint in cardiovascular outcome trials because these three events represent the outcomes patients and clinicians care most about preventing.
The SELECT Trial: The Landmark Result
SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) extended this finding to a new population: people with established cardiovascular disease but without type 2 diabetes. This is the trial that repositioned semaglutide from a metabolic drug to something with broader cardiovascular application.
The trial enrolled 17,604 patients — average age 62, average BMI 33, average A1C of 5.8% (just into the pre-diabetes range, but not diabetic). Nearly all were already on statins and antiplatelet therapy. These were well-treated patients with documented prior heart attack, stroke, or peripheral artery disease. The trial ran for an average of 40 months.
The result: a 20% relative risk reduction in MACE for semaglutide 2.4mg versus placebo. Non-fatal heart attack was reduced by 28%. Cardiovascular death trended down. All-cause mortality dropped from 5.2% to 4.3%.
Crucially, average weight loss in SELECT was only about 9.4% — lower than the 15% seen in the STEP trials for obesity. Yet the cardiovascular benefit appeared early, with the event curves separating almost immediately — before substantial weight loss could explain the effect.
CRP (a marker of systemic inflammation) dropped significantly in the semaglutide group. Triglycerides fell 18%. Non-HDL cholesterol declined. These metabolic improvements don't fully explain a cardiovascular benefit that appears this early, which has driven serious interest in the question of whether GLP-1R signaling in the heart and vasculature is doing direct work.
The FLOW Trial: Kidney Protection
FLOW (Semaglutide Treatment of Kidney Disease) added another dimension. The trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease — estimated GFR between 25–75, with significant urinary albumin. These are high-risk patients: 95% were already on ACE inhibitors or ARBs, 80% on statins, 61% on insulin.
The trial was stopped early after a median follow-up of 3.4 years because interim analyses showed such clear benefit that randomizing patients to placebo was no longer ethical.
The results: a 24% relative reduction in the primary kidney composite (first occurrence of kidney failure, a 50% sustained decline in GFR, or death from kidney or cardiovascular disease). Cardiovascular death was reduced by 29%. All-cause mortality dropped 20%.
Weight loss in FLOW was modest — about 4 kg more than placebo, roughly 5–6% total body weight loss. This is far below the 10% threshold typically cited for cardiovascular benefit from weight loss alone. Something else is happening.
GLP-1 receptors are expressed in the kidney, particularly in the tubules and vasculature. Semaglutide appears to reduce intraglomerular pressure — the hypertensive pressure within the kidney's filtration units that drives scarring and dysfunction over time. It also reduces renal inflammation. These are mechanisms independent of weight loss, and they match the magnitude and pattern of benefit seen in the trial.
Note(The SGLT2 inhibitor context)
Only 16% of FLOW participants were on SGLT2 inhibitors at baseline — medications like empagliflozin (Jardiance) that are now standard of care for diabetic kidney disease. The kidney benefit in FLOW was seen primarily in those NOT on SGLT2 inhibitors. The obvious clinical question — does adding semaglutide to an SGLT2 inhibitor provide additional kidney protection? — hasn't been definitively answered. Trials are being designed.
Direct Cardiac Effects vs. Weight-Mediated Benefit
The honest answer is: both, and the relative contributions aren't fully understood.
GLP-1 receptors are expressed in cardiomyocytes (heart muscle cells), the sinoatrial node, and coronary vasculature. GLP-1 signaling has demonstrated anti-inflammatory and anti-fibrotic effects in cardiac tissue in preclinical studies. The STEP-HFpEF trial showed that semaglutide dramatically improved quality of life and six-minute walk distance in patients with obesity and heart failure with preserved ejection fraction — a condition driven largely by cardiac stiffening, not just body weight. Patients gained an average of 21 meters on the six-minute walk test versus 1 meter for placebo.
That the curves in SELECT separate early, before significant weight loss, and that the harmony trial (albiglutide) showed cardiovascular protection despite minimal weight loss, both suggest direct drug effects beyond what the scale shows.
What's equally clear: weight loss matters. Patients who lost more weight in these trials tended to have better outcomes. The mechanism is almost certainly additive — reduced inflammatory burden, improved lipid profiles, lower intraglomerular pressure, direct GLP-1R effects on cardiac tissue, and reduced atrial fibrillation risk (meta-analyses suggest GLP-1s reduce arrhythmia risk, driven partly by weight loss).
What This Means If You're Not Diabetic
If you're taking a GLP-1 for obesity and you have a prior heart attack, stroke, peripheral artery disease, or high calculated cardiovascular risk, SELECT is directly relevant to you. The drug is doing cardiovascular work beyond what appears on the scale or in your A1C.
This reframes the cost-benefit calculation for long-term use. The argument "I've hit my weight goal, should I stop?" looks different when cardiovascular protection is part of the equation.
The Neurological Signal
Early-stage trials are producing signals worth watching. A phase 2b trial of liraglutide in early Alzheimer's disease (ELAD) showed 18% slower cognitive decline over 12 months and 50% less brain volume loss in memory-related regions compared to placebo — though the primary endpoint (cerebral glucose metabolism) was not met. Phase 3 trials with semaglutide are underway.
A French trial of lixisenatide in early Parkinson's disease showed that the drug prevented motor progression over 12 months, while the placebo group worsened. GLP-1 receptors are expressed throughout the brain, and GLP-1 signaling has demonstrated neuroprotective properties in animal models.
These are early data. No neurological indication is established. But the pattern — a drug originally understood to lower blood sugar revealing benefits across heart, kidney, and nervous system — suggests the GLP-1 receptor is involved in far more physiology than the original diabetes indication implied.
Intuition(Why this matters beyond the trials)
Cardiovascular disease kills more people with obesity and diabetes than almost any other complication. A drug that reduces heart attacks and strokes by 20–28% in high-risk patients — on top of standard statin and antiplatelet therapy — is not a marginal addition. It's a primary intervention. The framing of GLP-1s as "weight loss drugs" undersells what the outcome data actually shows.
User Sentiment
Example(What the community says)
People who've seen the SELECT and FLOW data tend to have a strong reaction: they weren't expecting it. A common thread in forums and patient communities is the realization that the drug may be doing more than the number on the scale suggests — and for people who feel guilty about the cost or wonder if they "still need" it after losing weight, this data often changes that calculation. Cardiologists who were initially skeptical are now among the most vocal advocates. The phrase "side effects include reduced heart attacks" has become something of a rallying point for the community.
Who It's For
This post is for anyone on a GLP-1 who has cardiovascular risk factors — prior heart attack, stroke, peripheral artery disease, or significant risk scores — and wants to understand what the drug is actually doing beyond weight management. It's also for people with chronic kidney disease and type 2 diabetes weighing medication options, and for anyone trying to make sense of "should I stay on this long term."
Summary(The short version)
GLP-1 drugs were required to prove they didn't cause heart problems. Instead, they reduced heart attacks by 20–28% (SELECT), kidney disease progression by 24% (FLOW), and cardiovascular death in multiple trials. Some of this benefit appears independent of weight loss — GLP-1 receptors in the heart, kidney, and brain appear to be doing direct work. For high-risk cardiovascular patients, these drugs are more than metabolic therapy. Early neurological data for Alzheimer's and Parkinson's is intriguing but not yet established.